MYC-mediated upregulation of PNO1 promotes glioma tumorigenesis by activating THBS1/FAK/Akt signaling

Xu Chen, Zheng-Qian Guo, Dan Cao, Yong Chen and Jian Chen

Abstract

PNO1 has been reported to be involved in tumorigenesis, however, its role in glioma remains unexplored. In the present study, PNO1 expression in glioma from on-line databases, cDNA, and tissue microarrays was upregulated and associated with poor prognosis. PNO1 knockdown inhibits tumor cell growth and invasion both in vitro and in vivo; whereas PNO1 overexpression promoted cell proliferation and invasion in vitro. Notably, PNO1 interacted with THBS1 and the promotion of glioma by PNO1 overexpression could be attenuated or even reversed by simultaneously silencing THBS1. Functionally, PNO1 was involved in activation of FAK/Akt pathway. Moreover, overexpressing MYC increased PNO1 promoter activity. MYC knockdown decreased PNO1 and THBS1 expression, while inhibited cell proliferation and invasion. In conclusion, MYC-mediated upregulation of PNO1 contributes to glioma progression by activating THBS1/FAK/Akt signaling. PNO1 was reported to be a tumor promotor in the development and progression of glioma and may act as a candidate of the specific target in glioma treatment.

Introduction

Glioma is one of the most common primary malignant tumors in the central nervous system and is divided by The World Health Organization into four grades: low-grade (Grades I and II) are well-differentiated and have low malignancy and high-grade (Grades III and IV) that are poorly differentiated and highly malignant.¹ And high-grade gliomas, which account for more than 50% of all gliomas have been considered as a major threat to human health.² Nowadays, despite great advances in therapeutic interventions, such as surgical resection, oral alkylating agents, and radiation, the prognosis in glioma patients remains poor.³,⁴ Therefore, exploring the underlying molecular mechanisms of glioma development urgently needed. Significant, there is growing evidence that identification of novel prognostic biomarkers is important for glioma treatment.

Thrombospondin1 (THBS1), one of the important components of extracellular matrix, was first discovered in platelets but has now been involved in regulating tumor development, including glioma.⁵–⁷ It has been reported that THBS1 acts as a stimulator of focal adhesion kinase (FAK, also known as PTK2).⁸,⁹ Importantly, a role for FAK activation in GBM cell invasion and migration has been reported.¹⁰ Thus, THBS1 and FAK may serve as the potential therapeutic target for GBM.

In this study, we found that ribosome assembly factor PNO1 was upregulated in glioma tissues and promoted cell growth of glioma cells. As is known, the RNA-binding protein partner of NOB1 (PNO1) is essential in ribosome biogenesis.¹¹–¹³ In addition, increasing evidence suggests that ribosome biogenesis plays important roles in cell growth and proliferation of many cancers, including glioma.¹⁴–¹⁷ Thus, inhibiting ribosome biogenesis might provide new opportunities for cancer treatment. However, there are few studies of the ribosome-related function of
PNO1 in cancers so far. Therefore, cDNA microarray analysis, high-throughput sequencing technologies, online databases analysis, biochemistry, and molecular biology were applied to evaluate PNO1 as a prognostic biomarker and its underlying molecular mechanisms of glioma development.

Results
Identification of PNO1 as a novel target in glioma
In our study, we first utilized three GBM tissues and three normal brain tissues for microarray analysis and found that a total of 3461 genes were differentially expressed, of which 1652 were upregulated and 1809 were downregulated (Fig. 1A, B). To identify potential oncogenes, we focused on six upregulated genes that have not been studied in glioma-related research, including MS4A7, DPYSL3, CYBB, PNO1, STOM, and HNMT (Fig. 1C). We knocked down the selected genes in U251 cells with lentivirus-transduced target-shRNA and the cell growth were detected by high-content screening (Fig. 1D, E). The results showed that the cell growth was significantly inhibited in shPNO1, shSTOM, and shHNMT groups (Supplementary Fig. S1A). PNO1 was chosen for subsequent studies because of its most obvious effect on cell growth. We found that PNO1 was upregulated in glioma cells both in protein and mRNA levels (Supplementary Fig. S1B, C); lentivirus encoding shRNAs specific against PNO1 were effective, of which, shPNO1-2 was the most effective shRNA (Supplementary Fig. S1D, E).

PNO1 is highly expressed in glioma tissues and predicts poor prognosis
To further confirm the expression pattern of PNO1 in glioma, we first investigated the PNO1 protein expression levels in 141 glioma tissues (55 LGG and 86 GBM) and 24 normal tissues by IHC. The results showed that PNO1 was obviously upregulated in tumor tissues and the higher PNO1 expression was significantly correlated with recurrence rates and advanced pathological grading (Fig. 2A, D). Based on detailed survival information from the glioma patients, the cutoff value for PNO1 was set by the median method for further survival analysis. The results indicated that the high expression of PNO1 was positively associated with the poor prognosis of glioma patients, such as overall survival (OS, \( P = 0.000 \)) and disease-free survival (DFS, \( P = 0.000 \)) (Fig. 2E). Bioinformatic analyses of public datasets using GEPIA2 and CO-IP revealed that PNO1 was upregulated at mRNA levels in GBM and predicted poor prognosis, which was consistent with the previous IHC results (Fig. 2F–H). The PNO1 protein and mRNA expression levels were also elevated in glioma tissues by RT-PCR and western blot (Fig. 2I, J).

PNO1 knockdown inhibits GBM cell proliferation and metastasis in vivo
Mice xenograft models were used through subcutaneous injection of U87 cell models to verify the effect of U87 knockdown on tumor growth in vivo. The measurement of tumor volume started at day after tumor inoculation and end up with day 18. The results of which illustrated a slower increase in tumor volume and less weight compared with control (Fig. 3A, B). The expression of PNO1 at the protein level in tumors was shown in Fig. 3C. In vivo imaging of this model confirmed the effect of PNO1 on suppressing tumor growth (Fig. 3D). Moreover, Ki-67 staining was used to detecting proliferative activity of tumors, which was obviously weaker in shPNO1 group than shCtrl group (Fig. 3E). In addition, we established metastasis mouse models by intravenous injection. After six weeks, the mice were sacrificed, and images were taken by a Living Image System (PerkinElmer). We found that U87 cells infected with shCtrl metastasized to the brain and lung, whereas there was no visual metastasis in shPNO1 group (Fig. 3F).

PNO1 promotes GBM cell proliferation and invasion in vitro
In cultured U251, U87, and SHG-44 cells, PNO1 knockdown decreased cell growth and increased cell apoptosis (Fig. 4A, B). PNO1 overexpression increased colony formation, cell viability, and cell invasion; while PNO1 knockdown shown the opposite (Fig. 4C–E). The PNO1 expression at protein and mRNA levels in U251, U87, and SHG-44 cell lines were verified by western blotting and RT-PCR, which indicated the target cells were successfully infected with lentivirus (Fig. 4F, G).

THBS1 acts as the potential target of PNO1 in the regulation of glioma
To further explored the mechanism of PNO1 on glioma, microarray analysis between shPNO1 and shCtrl groups of U251 cells was performed and revealed 1122 DEGs, including 650 downregulated DEGs and 472 upregulated DEGs. KEGG Pathway Enrichment Analysis of these DEGs using Cytoscape indicated that PNO1 may participate in several functional pathways involved in cell proliferation and metastasis, including focal adhesion and PI3K-Akt signaling pathway (Fig. 5A). Many intersection DEGs, including CCND1, RAC1, PRKCA, THBS1, and AKT3, have been reported to involve in glioma tumorigenesis and were further confirmed by RT-PCR in U251-shPNO1 cells (Fig. 5B). Through the STRING program, THBS1 appeared to be the potential target of PNO1 (Fig. 5C).
Co-immunoprecipitation (CO-IP) assay and western blot analysis suggested that PNO1 overexpression led to an
increase of THBS1 in U251 cells (Fig. 5D–F). Furthermore, we confirmed that the promotion of PNO1 overexpression on glioma cell growth and invasion could be rescued by downregulated THBS1 (Fig. 5G, H). Moreover, the results from on-line datasets analysis indicated that THBS1 was upregulated in GBM patients and predicts poor prognosis, which was also positively correlated with PNO1 expression in glioma patients (Supplementary Fig. S2A–D).

In summary, THBS1 showed similar regulatory effects on the development of glioma with PNO1.

**PNO1 activates FAK-Akt signaling through THBS1**

Consistent with our array data, we confirmed the protein expression of THBS1, phosphorylation levels of FAK, Akt, and the focal adhesion maker Paxillin by western blotting (Fig. 6A and Supplementary Fig. S3A).
Fig. 2 PNO1 is a specific prognostic biomarker in glioma tissues. A Representative images of normal tissues and glioma tissues showing PNO1 expression (50 µm). B PNO1 protein levels in 141 glioma tissues (55 LGG and 86 GBM) and 24 normal tissues were determined by IHC. C Correlation analysis between the PNO1 IHC score and tumor recurrence. D Correlation analysis between the PNO1 IHC score and tumor Grade. E Kaplan–Meier survival curve analysis showing the correlation between the PNO1 IHC score and OS (left) and DFS (right) in glioma patients. F PNO1 mRNA expression in 163 GBM tissues and 207 normal tissues were analyzed using online glioma database from GEPIA2. \( * P < 0.05 \). G Correlation analysis between the PNO1 mRNA expression and tumor Grade using online glioma database from CGGA. H Kaplan–Meier survival curve analysis showing the correlation between the PNO1 mRNA expression and OS in primary or recurrent glioma patients using online glioma database from CGGA. Western Blotting (I) and RT-PCR (J) showing PNO1 protein and mRNA levels between three GBM tissues (T) and three normal tissues (N). \( n = 3, \ * P < 0.05, \ ** P < 0.01, \ *** P < 0.001 \).
Next, we performed PF562271 (FAK inhibitor, 10 µM) and MK2206 (Akt inhibitor, 10 µM) to inhibit the FAK/Akt signaling. As shown in Fig. 6B and Supplementary Fig. S3B, PF562271 distinctly downregulated the phosphorylation levels of both FAK and Akt in U251 cell lines, respectively. In addition, MK2206 visibly decreased the phosphorylation levels of Akt, but it failed to attenuate the phosphorylation levels of FAK, suggesting that Akt might serve as downstream of FAK in this study (Fig. 6C and Supplementary Fig. S3C). Moreover, PF562271 has no observable effects on cell viability (Fig. 6D) while MK2206 overtly decreased cell growth (Fig. 6F). Notably, overexpression of PNO1-induced increased cell invasion was profoundly reversed by treatment with PF562271 or MK2206 in U251 cell lines (Fig. 6E, G).

Transcription factor MYC positively regulates PNO1 expression in glioma

To further explore the upstream mechanism of PNO1 on glioma, we identified MYC as a potential transcription factor of PNO1 using TFBIND screening of transcription factor binding sites combined with DEGs from KEGG Pathway Enrichment Analysis. As shown in Fig. 7A, knockdown of PNO1 not only suppressed PNO1 expression but also reduced MYC expression in U251 cells. Moreover, the dual luciferase assay indicated that PNO1 promoter activity is increased when MYC was overexpressed in U251 cells (Fig. 7B). These findings demonstrated that MYC was regarded as an upstream transcription factor of PNO1 in glioma. Furthermore, we found that MYC knockdown overtly decreased expression of PNO1 and THBS1 at mRNA levels in glioma cells.
Fig. 4 (See legend on next page.)
MYC knockdown in U251 cells visibly induced cell apoptosis and decreased cell viability (Fig. 7D, E). It also inhibited cell invasion in U251 cells (Fig. 7F). Besides, MYC knockdown reduced the protein levels of PNO1 and THBS1, as well as the genes involved in the FAK/Akt signaling pathway (Fig. 7G). In addition, according to the data analysis of online tools (GEPIA2 and CGGA databases), we found that MYC expression was positively correlated with PNO1 and THBS1.
correlated with PNO1 (Supplementary Fig. S2E–G). All of above results suggest that MYC overexpression may help drive glioma by triggering PNO1 overexpression.

**Discussion**

Several studies have proven that PNO1 acts as an essential role in tumorigenesis and development; however, its role in glioma remains poorly defined. In this study, we provided evidence from clinical specimens and glioma cell lines that PNO1, driven by the transcription factor MYC, significantly contributes to glioma cell proliferation and metastasis via regulating the expression of THBS1, leading to the phosphorylation of FAK and Akt (Fig. 7H). These findings revealed a new oncogenic signal axis, MYC/PNO1/THBS1/FAK/Akt, in the modulation of cell proliferation and metastasis and provided new insights into how PNO1 works in the progression of glioma. Consequently, interfering in this signal axis could be an efficient way to inhibit glioma development and this is the first report showing the roles and mechanism of PNO1 as an oncogene in glioma.

To further explore the underlying mechanism of oncogenic effects of PNO1 in glioma, we applied cDNA microarray analysis combined with KEGG pathway enrichment analysis to identify these DEGs in U251 cells after treated with shPNO1 or shCtrl. Our results suggested that PNO1 may participate in several functional pathways involved in cell proliferation and migration,
such as focal adhesion and PI3K-Akt signaling pathway. Coincidentally, the focal adhesion kinase (FAK)/Akt signaling was proved to participate in mediating the inhibition of cell migration and invasion of GBM cells.\(^{28}\)

However, the regulatory molecular mechanism of PNO1 on these pathways have not yet been fully determined. Intriguingly, the CO-IP experiments in this study indicated that THBS1 interacted with PNO1 in U251 cells, which has been reported to be associated with tumor development and progression in several types of cancer.\(^9\)

Notably, THBS1 was highly expressed in high-grade glioma patients, and THBS1 silencing inhibited GBM cell growth and invasion.\(^{23,29}\) In our study, we observed that the inhibition of THBS1 knockdown on glioma cell growth and invasion could be rescued by PNO1 overexpression. Therefore, we provide evidence that THBS1 acts as a novel target of PNO1 in the progression of glioma. Whereas, the mechanisms for THBS1 regulation in glioma was still limited. Previous studies have proven that THBS1 could modulate FAK phosphorylation to regulate focal adhesion dynamics.\(^9,30\) Importantly, inhibition of PI3K activity led to both a decrease in FAK phosphorylation and a decrease in the ability of cells to migrate in response to a directed gradient of THBS1.\(^{31}\)

Other study reported that FAK had since been shown to transduce many of the matrix-dependent effects on cell proliferation, migration, and survival.\(^{32}\) Similarly, high FAK expression and activity in GBM is corrected with poor overall survival.\(^{28,33}\) Mechanistically, PNO1 interacted with THBS1. Here we provide evidence that PNO1

---

Fig. 7 Transcription factor MYC positively regulates PNO1 expression in glioma. A. RT-PCR showing PNO1 and MYC mRNA levels in U251 cells infected with shCtrl or shPNO1, \(n = 3, *P < 0.05, **P < 0.01, ***P < 0.001\). B. A dual luciferase assay was performed to determine the effect of MYC overexpression on transcription activity of PNO1 in U251 cells. C. RT-PCR showing MYC, PNO1 and THBS1 mRNA levels in U251 cells infected with shCtrl or shMYC, \(n = 3, *P < 0.05, **P < 0.01\). D. Effects of MYC on cell apoptosis of U251 cells infected with shCtrl or shMYC, \(n = 3, **P < 0.01\). E. Effects of MYC on growth of U251 cells infected with shCtrl or shMYC, \(n = 3, **P < 0.01, ***P < 0.001\). F. Effects of MYC on cell invasion of U251 cells infected with shCtrl or shMYC, \(n = 3, **P < 0.01\). G and H. Western Blotting showing MYC, PNO1, THBS1 and FAK/AKT signaling protein levels in U251 cells infected with shCtrl or shMYC. H. Schematic depicting the regulation of PNO1 in GBM cells.
positively regulated the THBS1/FAK/Akt signaling in GBM cells, which was further confirmed by using individual inhibitors targeting FAK or Akt. Therefore, our study indicates PNO1 as a novel regulator in THBS1/FAK/Akt signaling pathway-mediated effects on GBM cell proliferation and metastasis.

To further explore the upstream mechanism of PNO1 on glioma, we identified MYC as a potential transcription factor of PNO1 using web-based screening (TFBIND) of transcription factor binding sites combined with DEGs from KEGG Pathway Enrichment Analysis. It has been demonstrated that MYC regulates transcriptional amplification by super enhancers, which was a main hallmark of cancer.\(^ {34}\) We uncovered that MYC knockdown overtly decreased expression levels of PNO1 and THBS1 mRNA and protein in glioma cells, leading to the phosphorylation of FAK and Akt. Recent studies had shown that MYC overexpression was positively correlated with glioma grade and that increased MYC level was observed in approximately 60-80% gliomas.\(^ {35}\) Inhibition of MYC repressed the proliferation of tumor cells, damages cell activity, and promoted apoptosis.\(^ {36}\) Indeed, our data showed that MYC knockdown in U251 cells visibly decreased anti-apoptosis, cell viability, and cell invasion. MYC is a key integrator of growth-regulatory and oncogenic signaling pathways. We also identified that MYC expression correlated obviously with PNO1 based on data from on-line glioma databases analysis. Our study is the first to reveal the relationship between PNO1 and MYC. Relevantly, others have proposed that efficient of THBS1 is critical for MYC-induced metastatic phenotypes in medulloblastoma.\(^ {37}\) Similarly, MYC amplification may play a crucial role in the angiogenic phenotype through downregulating THBS1 in angiosarcomas.\(^ {38}\) All of above results suggest that MYC overexpression may help drive glioma by triggering PNO1 or THBS1 overexpression. It was consistent with previous studies that activation of MYC was involved in tumor formation by targeting ribosome biogenesis.\(^ {2,39-43}\) However, how MYC regulates PNO1 expression needs further in-depth study.

In conclusion, our findings show that MYC-mediated upregulation of PNO1 contributes to glioma progression by activating THBS1/FAK/Akt signaling. In addition, several small compounds targeting FAK, such as PF562271 and VS-4718, have been launched for conducting clinical trials. Therefore, understanding the roles and mechanism of PNO1 will provide novel therapeutic strategies in glioma.

Materials and methods

Ethics statement

This study was compiled with the ethical guidelines of the Helsinki Declaration and approved by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (IACUC-2020-02-A).

Patients and tissue specimens

Three glioma tissues and three normal brain tissues were obtained from (Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology). Tissue chips were purchased from OUTDO BIO-TECH (Shanghai, China). Clinicopathologic characteristics of patients could be seen in Supplementary Table S1. Samples stained with hematoxylin and eosin were verified by experienced pathologists.

Microarray analysis

The detection of gene expression profile in glioma tissues (n = 3) and normal brain tissues (n = 3), as well as in U251 cells infected with shCtrl or shPNO1 by microarray analysis. Total RNA was extracted by the RNeasy kit (Sigma). The concentration of total RNA was determined by NanoDrop 2000 (Thermo Fisher Scientific). RIN value was evaluated with Agilent 2100 and Agilent RNA 6000 Nano Kit (Agilent). RNA sequencing was performed with Affymetrix human GeneChip PrimeView according to the manufacturer’s instruction and the outcomes were scanned by Affymetrix Scanner 3000 (Affymetrix). Raw data statistical significance assessment was accomplished using a Welch t-test with Benjamin–Hochberg FDR. Significant difference analysis and functional analysis based on KEGG pathway enrichment analysis were executed.

Cell culture and transfection

U87, U251, SHG-44, and HEB cell lines were purchased from BeNa Technology (Beijing, China). Cells were identified by STR and the test results for mycoplasma were negative. All cell lines were grown in 90% DMEM with 10% FBS. Cells were grown at 37 °C in a humified atmosphere of 5% CO₂. All the plasmids involved in this paper were obtained from Genechem (Shanghai, China). The information of sequences could be found in Supplementary Table S2. Glioma cell lines in logarithmic phase were infected with lentivirus vectors with polybrene at a multiplicity of infection of 10 for 12 h, and then maintained in the new fresh complete medium. After 72 h infection, when the infection efficiency of lentivirus on cells was observed over 85% by fluorescence microscope (Olympus), the cells were harvested for the follow-up experiments.

Real-time quantitative PCR

Total RNA from the cell lines or tissue samples was isolated, respectively using TRIZOL (Sigma) following the manufacturer’s instructions. Reverse transcription of RNA (2.0 µg) to cDNA was performed using the PrimeScript RT reagent kit (Takara) following the manufacturer’s instructions. RT-PCR was carried out using the SYBR
Of Cell apoptosis

CCK8 assay

Celigo cell counting assay

Western blot

Immunohistochemical staining

Cell proliferation curve was drawn.

Colonies formation assay

Transwell invasion assay

Mouse models

Ki-67 staining assay

Cells and tissues were lysed in ice-cold RIPA buffer (Millipore) and protein concentration was detected by BCA Protein Assay Kit (HyClone-Pierce). The same amount of total protein from each group was separated by 12% SDS-PAGE and transferred onto a PVDF membrane (Bio-Rad Laboratory). The membranes were blocked with primary antibodies in TBST plus 5% non-fat milk. After washed with TBST, membranes were incubated with the appropriate secondary antibody. The signals were visualized using ECL-PLUS Kit (Amersham). Band intensities were quantified using Image J software (NIH). Antibodies used in IHC staining were listed in Supplementary Table S4.

Cells and tissues were incubated with PNO1 antibody (1:100, Sigma) at 4 °C overnight, then washed with phosphate-buffered saline (PBS) for 3 times, and incubated with horseradish peroxidase (HRP) conjugated goat anti-mouse IgG polyclonal antibody for 30 min at room temperature. DAB and hematoxylin were used to stain tissue slides. IHC scoring of patients was determined based on the total of the staining intensity and staining extent scores (0, undetectable; 1, weak; 2, moderate; 3, strong). Antibodies used in IHC staining were listed in Supplementary Table S3.

Cells were centrifuged at 1300 rpm and resuspended with 200 µL binding buffer. Evaluation of apoptosis was performed by Annexin V-APC staining flow cytometry method (eBioscience) according to the manufacturer’s protocol.

Lentivirus infected glioma cells were measured by CCK8 assay. Cells in the logarithmic phase were seeded onto 96-well plates (2000 cells/well) in 36 h. Cells viability was accomplished every day by Celigo image cytometer (Nexcelom Bioscience) and the cell proliferation curve was drawn.

CCK8 solution (10 µL, MCE) was incubated with cells for 3 h. The OD450 was measured by microplate reader (Tecan) on day 1, 2, 3, 4, and 5 which reflects the number of viable cells. The cell viability ratio was calculated.

Lentivirus infected glioma cells were measured by CCK8 assay. Cells in the logarithmic phase were seeded onto 96-well plates (2000 cells/well). CCK8 solution (10 µL, MCE) was incubated with cells for 3 h. The OD450 was measured by microplate reader (Tecan) on day 1, 2, 3, 4, and 5 which reflects the number of viable cells. The cell viability ratio was calculated.

Lentivirus infected U87 cell suspensions at a density of 2 × 10^7 cell/ml. After 6 weeks, the mice were sacrificed and taken in vivo images. Tumor images were obtained by a Living Image System (PerkinElmer). Mice were purchased from Shanghai Ling chang Experimental Animals Co., Ltd and randomly divided into two groups (10 mouse/group) using a computer-based random order generator. Tumor growth was assessed twice a week using a caliper and tumor volumes (V) were estimated as \( V = \pi/6 \times L \times W \times L \) and \( W \) was tumor length and width, respectively. Due to overt tumor volume, the experimenter could not be blinded to whether the animal was injected with shPNO1 or shCtrl. The tumor tissues were removed for Ki-67 immunostaining. If the animal dies prematurely, preventing the collection of tumor volume and histological data, the data will be excluded from the analysis.

Tissue slides were blocked with 3% PBS-H2O2 and were incubated with primary antibody Ki-67 at 4 °C overnight. Then slides were incubated with HRP goat anti-rabbit IgG at room temperature for 2 h. Finally, all slides were...
stained by Hematoxylin (# BA4041, Baso) and Eosin (# BA4022, Baso).

Promoter activity assay

Briefly, U251 cells were co-transfected with MYC overexpression plasmid (500 ng), Renilla luciferase reporter (20 ng), and luciferase reporter plasmid (500 ng) using Lipofectamine™ 3000 Transfection reagents (Thermo). After transduced for 48 h, cells were washed twice with PBS and then lysed in 1 × PLB from the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) for 30 min. Aliquots of supernatant (20 µL) were added to 96-well plates, followed by 40 µL luciferase assay reagent (Promega) at room temperature. Luciferase activity was measured immediately using a luminometer (Orion II Microplate Luminometer, Berthold Detection Systems, Pforzheim, Germany). Data were normalized to the results obtained for the internal control Renilla luciferase.

Statistical analysis

Cell experiments were performed in triplicate and data were expressed as the mean ± SD. Student’s t test was used to analyze the statistical significance. Multiple groups were compared by one-way ANOVA. All statistical analysis was performed using SPSS 22.0 (IBM, SPSS) and GraphPad Prism 8.01 (GraphPad Software). P < 0.05 was considered statistically significant. Kaplan-Meier survival analysis was performed using the log-rank test.

Acknowledgements

Thanks are due to Jenny for assistance with the English editing. This work was supported by State Scholarship Fund of China Scholarship Council (20180851007, 201708510596).

Author contributions

X.C. designed this program, X.C. performed the experiments, Z.Q.G. and D.C. conducted the data collection and analysis. Y.C. and X.C. produced the manuscript which was checked by J.C. All the authors have confirmed the submission of this manuscript.

Conflict of interest

The authors declare no conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-03532-y.

Received: 18 September 2020 Revised: 8 January 2021 Accepted: 12 January 2021 Published online: 04 March 2021

References

1. Ostrom, Q. T. et al. Citrus statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 20, iv1–iv86 (2018).
2. Cheng, M. et al. Super-enhancers: a new frontier for glioma treatment. Biochim. Biophys. Acta Rev. Cancer 188353, 2020 (1873).
3. Davis, M. E. Glioblastoma: overview of disease and treatment. Clin. J. Oncol. Nurs. 20, S2–S8 (2016).
4. Cheng, F. & Guo, D. Met in glioma: signaling pathways and targeted therapies. J. Exp. Clin. Cancer Res. 38, 270 (2019).
5. Gahtan, V. et al. Thrombospondin-1 induces activation of focal adhesion kinase in vascular smooth muscle cells. J. Vasc. Surg. 29, 1031–1039 (1999).
6. Adams, J. C. & Lawler, J. The thrombospondins. Int. J. Biochem. Cell Biol. 36, 961–968 (2004).
7. Frikje, V. et al. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res. 71, 4658–4668 (2011).
8. Wang, X. J. et al. Thrombospondin-1-induced migration is functionally dependent upon focal adhesion kinase. Vasc. Endovasc. Surg. 42, 256–262 (2008).
9. Shen, J. et al. Hippo component complex promotes cancer cell adhesion and tumour aggressiveness via transcriptionally activating matrix metalloproteinase 2. J. Exp. Clin. Cancer Res. 37, 175 (2018).
10. Fan, Z. et al. A tropomyosin-like meretrix meretrix linnaeus polypeptide inhibits the proliferation and migration of glioma cells. Mol. Med. Rep. 11, 2757–2764 (2015).
11. Wang, X. et al. Ptp1b is a transcription factor, and its functions related to the immune response in glioma. J. Cell. Physiol. 229, 100092 (2014).
12. Zhou, G. J. et al. Cloning and characterization of a novel human rna binding domain protein, pno1. DNA Seq. 15, 219–224 (2004).
13. Miura, T., Kuze, S. & Oh, H. Cloning and characterization in pichia pastoris of pno1 gene required for phosphomannosylation of n-linked oligosaccharides. Gene 324, 129–137 (2004).
14. Li, G. et al. Pdia3 cooperates with smad3/4 complex to suppress mxk signaling in breast cancer. J. Exp. Clin. Cancer Res. 37, 175 (2018).
15. Pellegrini, J. et al. Ribosome biogenesis in cancer: New players and therapeutic avenues. Cancer Biol. Med. 13, 180–186 (2016).
16. Collins, J. C. et al. Ribosome biogenesis factor ltv1 chaperones the assembly of the small subunit head. Cell Biol. 217, 4141–4154 (2018).
17. Saito, K. et al. Functional analysis of a novel glioma antigen, eftud1. Cancer Biol. Ther. 24, 286–291 (2013).
18. Turner, K. M. et al. Genomically amplified akt3 activates DNA repair pathway and promotes glioma progression. Proc. Natl Acad. Sci. U.S.A. 112, 3424–3429 (2015).
19. Feng, X. et al. Hypoxia-induced acetylation of pak1 enhances autophagy and promotes brain tumorogenesis via phosphorylating atg5. Autophagy, 1–20 (2020).
20. Liu, P. et al. Par6 regulates cell cycle progression through enhancement of akt/p38/gsk3beta signaling pathway activation in glioma. J. Neurooncol. 160, 1618–1629 (2020).
21. Perrett, J., Thomas, G. & Volarevic, S. Ribosome biogenesis in cancer: New players and therapeutic avenues. Nat. Rev. Cancer 18, 51–63 (2018).
22. Collins, J. C. et al. Ribosome biogenesis factor ltv1 chaperones the assembly of the small subunit head. J. Cell Biol. 217, 4141–4154 (2018).
23. Saito, K. et al. Functional analysis of a novel glioma antigen, eftud1. Neuro Oncol. 16, 1618–1629 (2020).
24. Turner, K. M. et al. Genomically amplified akt3 activates DNA repair pathway and promotes glioma progression. Proc. Natl Acad. Sci. U.S.A. 112, 3424–3429 (2015).
25. Tsutsui, T. et al. Glioma-derived extracellular vesicles promote tumor progression by conveying wt1. Oncology 279, 961–968, 2020 (2016).
26. Lin, C. et al. Importance of pno1 for growth and survival of urinary bladder carcinoma: role in cancer regression in vivo. J. Cell. Mol. Med. 24, 1504–1515 (2020).
27. Lin, D. et al. Pno1, which is negatively regulated by mir-340-5p, promotes lung adenocarcinoma progression through notch signaling pathway. Oncogenesis 9, 58 (2020).
28. Jiang, K. et al. Mob2 suppresses gbm cell migration and invasion via regulation of fetal/akt and camp/pka signaling. Cell Death Dis. 11, 230 (2020).
29. Daubon, T. et al. Deciphering the complex role of thrombospondin-1 in glioblastoma development. Nat. Commun. 10, 1146 (2019).
30. Or, A. W., Pallero, M. A., Xiong, W.-C. & Murphy-Ullrich, J. E. Thrombospondin induces rhoa inactivation through fak-dependent signaling through the fak-cdc42 focal adhesion disassembly. J. Biol. Chem. 279, 48983–48992 (2004).
31. Lynn Joanne, S. et al. Phosphatidylinositol 3-kinase and focal adhesion kinase are early signals in the growth factor-like responses to thrombospondin-1.
seen in human vascular smooth muscle. *Arterioscler. Thromb. Vasc. Biol.* 19, 2133–2140 (1999).

32. Parsons, J. T. Focal adhesion kinase: the first ten years. *J. Cell Sci.* 116, 1409 (2003).

33. Shao, Y. et al. Alternative splicing-derived intersectin1-l and intersectin1-s exert opposite function in glioma progression. *Cell Death Dis.* 10, e431 (2019).

34. Kress, T. R., Sabò, A. & Amati, B. Myc: Connecting selective transcriptional control to global rna production. *Nat. Rev. Cancer* 15, 593–607 (2015).

35. Chen, X. et al. Mir-9 promotes tumorigenesis and angiogenesis in human glioma. *J. Exp. Clin. Cancer Res.* 38, 99 (2019).

36. Annibali, D. et al. Myc inhibition is effective against glioma and reveals a role for myc in proficient mitosis. *Nat. Commun.* 5, 4632 (2014).

37. Zhou, L. et al. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma. *Cancer Res.* 70, 8199 (2010).

38. Italiano, A. et al. The mir-17-92 cluster and its target thbs1 are differentially expressed in angiosarcomas dependent on myc amplification. *Genes, Chromosomes Cancer* 51, 569–578 (2012).

39. Bywater, M. J. et al. Inhibition of rna polymerase i as a therapeutic strategy to promote cancer-specific activation of p53. *Cancer Cell* 22, 51–65 (2012).

40. Devlin, J. R. et al. Combination therapy targeting ribosome biogenesis and rna translation synergistically extends survival in myc-driven lymphoma. *Cancer Discov.* 6, 59–70 (2016).

41. Hald, O. H. et al. Inhibitors of ribosome biogenesis repress the growth of mycn-amplified neuroblastoma. *Oncogene* 38, 2802–2813 (2019).

42. Destefanis, F., Manara, V. & Bellosta, P. Myc as a regulator of ribosome biogenesis and cell competition: a link to cancer? *J. Mol. Biol.* 427, 4237 (2020).

43. Kamijo, H. et al. Thrombospondin-1 promotes tumor progression in cutaneous t-cell lymphoma via cd47. *Leukemia* 34, 852–866 (2020).